Healthcare Industry News:  La Jolla Pharmaceutical Company 


 News Release - February 12, 2009

La Jolla Pharmaceutical Company Announces Negative Results of Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial

SAN DIEGO--(HSMN NewsFeed)--La Jolla Pharmaceutical Company (Nasdaq:LJPC ) announced today that the Independent Data Monitoring Board for the Riquent® Phase 3 ASPEN study has informed the Company that they have completed the first interim efficacy analysis and determined that continuing the study is futile. The Company has decided to stop the study, unblind the data and evaluate the results. The Company expects to provide additional guidance on its strategic options going forward in the near future.

Source: La Jolla Pharmaceutical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.